The state of teledermatology and companies developing neural networks for melanoma evaluation

Authored by: Biohedge analyst team

Type	In-depth investigation
Depth	In-depth
Client	Private Equity
Availability	Private

Contents

1. 1. Executive Summary
   2. Overview of Leading Teledermatology Companies
   3. Key Findings and Recommendations for Teledermatology Investment
   4. Background and History of Teledermatology
   5. Artificial Intelligence and Deep Learning for Skin Disorders 
   6. Overview of Teledermatology Market
   7. Global Skin Cancer Statistics and Trends for Various Skin Conditions
   8. Current Landscape of Teledermatology and AI that will drive Market Growth
   9. Market Opportunities and Challenges Analysis 
   10. Asynchronous and Synchronous Teledermatology
   11. 3Derm (U.S based company)
   12. MDLIVE (U.S based company)
   13. FirstDerm (U.S based company)
   14. 3Gen (U.S based company)
   15. MetaOptima (U.S based company)
   16. Ksyos (U.S based company)
   17. Ksyos (U.S based company)
   18. Teladoc Health Inc (U.S based company)
   19. Miiskin Health Inc (U.S based company)
   20. OnlineDoctor (E.U based company)
   21. Technology 2: Small Polypeptide based Killer Engagers (SPiKE)
   22. Barriers to Access Telemedicine Solutions
   23. Regulatory and Policy Conditions
   24. Industrial and technical solutions
   25. Deep Learning for eczema, melanoma and acne
   26. Market Analyses and Geographical Distribution of the Market
   27. Comparative Analysis Between Leading Teledermatology Companies
   28. Actions to Overcome Barriers and Policies
   29. Current and Potential Regulatory Approvals
   30. Economic Analysis for E.U and U.S
   31. Guidelines for Teledermatology and Conditions Treated
   32. Financial Viability and Return on Investment Risks and Challenges
   33. Scientific and Technical Risks
   34. Regulatory and Market Risks
   35. Competitive and Intellectual Property Risks Conclusion
   36. Summary of Findings
   37. Investment Recommendation Appendix
   38. Glossary of Terms
   39. References and Citations
   40. Supporting Documents and Data

Låst rapport: Analysen är begränsad till beställaren.